Clinical trial · Observational
Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA/CT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat/muscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Body Composition Changes | — | UNRESOLVED | — |
| Mechanism | — | UNRESOLVED | — |
| Obesity Rekated Cancer | — | UNRESOLVED | — |
| Survival | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From date of diagnosis until the date of death from any cause, assessed up to 10 years
- description
- The time from the start of follow-up to death (for any reason).
Secondary outcomes (2)
- measure
- Progression-free survival after diagnosis
- timeFrame
- From date of diagnosis until the date of first documented progression , assessed up to 10 years
- measure
- Time of recurrence and/or distant metastasis after diagnosis
- timeFrame
- From date of diagnosis until the date of first documented recurrence and/or distant metastasis, whichever came first, assessed up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years, regardless of gender. 2. Histologically or cytologically confirmed obesity-associated malignant tumors (e.g., breast cancer, colorectal cancer, gastric cancer, lung cancer, or thyroid cancer) with planned treatment after diagnosis (any treatment modality permitted). 3. No prior chemotherapy, radiotherapy, biologic therapy, immunotherapy, or other antitumor treatments for malignancy. Exclusion Criteria: 1. Patients with concurrent non-obesity-related malignancies. 2. History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin). 3. Patients with concurrent multiorgan dysfunction syndrome, autoimmune diseases, infectious diseases, neurological disorders, or psychiatric disorders.
References
Publications (0)
Data not yet available